Abstract
Background
Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC).
Methods
After identifying the recommended dose, patients with PARPi-naive BRCA-mutated or homologous recombination-deficient/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab. Tumour biopsies were collected pre-treatment, during single-agent rucaparib run-in, and after starting combination therapy.
Results
The most common adverse events with rucaparib 600 mg twice daily and atezolizumab 1200 mg on Day 1 every 3 weeks were gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia. Responding patients typically had BRCA-mutated tumours and higher pre-treatment tumour levels of PD-L1 and CD8 + T cells. Markers of DNA damage repair decreased during rucaparib run-in and combination treatment in responders, but typically increased in non-responders. Apoptosis signature expression showed the reverse. CD8 + T-cell activity and STING pathway activation increased during rucaparib run-in, increasing further with atezolizumab.
Conclusions
In this small study, rucaparib plus atezolizumab demonstrated acceptable safety and activity in BRCA-mutated tumours. Increasing anti-tumour immunity and inflammation might be a key mechanism of action for clinical benefit from the combination, potentially guiding more targeted development of such regimens.
Clinical trial registration
ClinicalTrials.gov (NCT03101280).
Similar content being viewed by others
Background
The treatment landscape in gynaecological cancers and triple-negative breast cancer (TNBC) has changed substantially in recent years. Poly(ADP-ribose) polymerase (PARP) is a validated target for ovarian cancer and TNBC, especially for patients with homologous recombination deficiency (HRD), including loss-of-function mutations on BRCA1, BRCA2, and other genes important for DNA damage repair (DDR) and genomic loss of heterozygosity (gLOH). Following single- or double-strand DNA breaks, PARP is rapidly recruited to the damaged sites, signalling other DDR effector proteins to repair the damage. PARP inhibitors (PARPis) block the recruitment of effector proteins and DDR, and also (to varying degrees according to the agent) trap PARP at the DNA replication fork to block transcription and translation [1, 2]. In patients with HRD tumours, PARPis can induce synthetic lethality leading to decreased DDR, cell cycle arrest, and apoptosis [3]. PARPis have become part of standard therapy, initially as maintenance for platinum-sensitive recurrent ovarian cancer [4,5,6], and now in the front-line maintenance setting for ovarian cancer (with or without anti-angiogenic therapy) [7,8,9]. PARPis are also part of standard therapy in pre-treated metastatic BRCA-mutated breast cancer [10, 11] and as adjuvant therapy for BRCA-mutated early breast cancer [12].
Immunotherapy with immune checkpoint inhibitors (ICIs), including agents targeting programmed cell death-ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1), has revolutionised cancer care for many solid tumours by potentially either reinvigorating exhausted tumour-specific cytotoxic CD8 + T cells or recruiting newly activated immune cells (ICs) to tumour sites [13]. This shifts the balance of the overall tumour immune microenvironment toward anti-tumour immune response. ICIs have become a standard of care in subsets of some tumour types, demonstrating clinically significant benefit in PD-L1-positive metastatic TNBC [14,15,16,17] and in early TNBC irrespective of PD-L1 status [18,19,20], but minimal efficacy in ovarian cancer [21,22,23,24,25].
As the treatment landscape evolves, clinical trials combining these approaches have been initiated, some of which include translational research objectives [26,27,28]. While such strategies have shown benefit in some patients, there remains a need to improve understanding of the underlying disease biology, mechanisms of action (MoAs), and the impact of these treatments within different subsets of patients, to try to determine whether precision medicine and individualised therapy can move into mainstream clinical practice in these settings.
Preclinical studies suggest that PARPis may synergise with ICIs to enhance anti-tumour immunity. First, reduced DDR resulting from PARPi leads to an accumulation of cytosolic DNA, which in turn activates the DNA-sensing cyclic GMP–AMP synthase (cGAS) stimulator of interferon genes (STING) pathway and increases type I interferons and other chemoattractant secretion [29]. Second, interferons and chemokines can attract ICs into the tumour vicinity and increase PD-L1 expression on tumour cells (TCs), thereby enhancing the effect of anti-PD-(L)1 agents [1]. PD-L1 expression on TCs can also be induced by an interferon-independent mechanism upon PARPi treatment [30]. Third, dead TCs can release tumour neoantigens and activate CD8 + T cells [1].
The predictive role of BRCA mutation/HRD for PARPi benefit in ovarian cancer has been observed consistently [31], as has the role of PD-L1 positivity for ICIs in metastatic TNBC [14, 16]. However, the biomarker interplay of BRCA1/2 and PD-L1 expression in patients receiving PARPis and ICIs in combination has not been explored in the clinical setting, and is relatively poorly understood. Translational work suggests that patients with BRCA-mutated ovarian cancer, which have more protein-coding mutations that can potentially be targeted by the immune system, may show enhanced response to ICIs [32]. These tumours also have higher PD-1 and PD-L1 expression in intratumoral ICs, and an elevated number of CD3-positive and CD8-positive tumour-infiltrating lymphocytes (TILs) [32]. This led to the hypothesis that immunotherapy targeting PD-(L)1 may preferentially benefit patients with BRCA-mutated or HRD tumours, although this effect was not seen in post hoc analyses of the IMagyn050 trial [33].
Therefore, we explored the combination of rucaparib (a PARPi) and atezolizumab (a monoclonal antibody targeting anti-PD-L1) in biomarker-selected populations of patients with advanced gynaecological cancers or TNBC. The study was designed to evaluate the safety profile and potential pharmacokinetic (PK) interactions of the combination. Collection of baseline and on-treatment tumour tissue biopsies provided a unique opportunity to examine exploratory endpoints assessing the effect of rucaparib and atezolizumab on DDR, cell cycle, cell death, and the tumour immune microenvironment, as well as baseline and longitudinal biomarker effects.
Methods
COUPLET (NCT03101280) was a multi-centre, two-part, open-label, non-randomised, Phase Ib study evaluating the combination of rucaparib and atezolizumab in patients with advanced gynaecological cancer or TNBC. Part 1 (dose finding) aimed to determine the recommended dose of rucaparib in combination with atezolizumab for further evaluation in Part 2 (dose expansion).
The primary objective was to evaluate the safety and tolerability of the combination by identifying dose-limiting toxicities (DLTs; Supplementary Table 1) that determined the maximum tolerated dose and identifying a potential recommended dose and schedule for subsequent assessments. Safety endpoints included the incidence, nature, and severity of adverse events (AEs) and DLTs according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. Secondary efficacy endpoints comprised objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, duration of response, progression-free survival (PFS) according to RECIST version 1.1, and overall survival (OS). The PK objective was to determine the PK of rucaparib and atezolizumab combination therapy in plasma and serum, with pre-specified parameters including steady-state maximum concentration observed (Cmax), time to maximum concentration (Tmax), and area under the concentration–time curve (AUC) for rucaparib and serum concentration of atezolizumab in Part 1, and minimum concentration during the dosing interval or trough concentration (Cmin) of rucaparib and serum concentration of atezolizumab in Part 2. The incidence of antidrug antibodies (ADAs) to atezolizumab was an additional secondary endpoint. The study also included pre-specified exploratory biomarker objectives: to evaluate predictive and pharmacodynamic biomarkers of response or resistance to combined rucaparib and atezolizumab therapy in tumour biopsies and blood; and to evaluate additional biomarkers of HRD and novel biomarkers and correlate them with response and/or clinical outcome, including efficacy and safety. Supplementary Table 2 describes biomarker-evaluable populations for the different assays. No formal statistical analyses were planned.
In Part 1 (dose-finding phase), patients with histologically confirmed ovarian or endometrial cancer who had received at least one prior line of therapy for metastatic disease received varying doses of oral rucaparib (400 mg twice daily in the first cohort, 600 mg twice daily in the second cohort, decreasing to 500 mg in the third cohort if necessary) in combination with a fixed dose of intravenous atezolizumab 1200 mg on Day 1. Cycles were repeated every 21 days and continued until unacceptable toxicity or disease progression if, in the investigator’s opinion, the patient would not derive clinical benefit from continued study treatment. It was planned to enroll ~six to 18 patients in up to three dose cohorts. The highest dose level demonstrating an acceptable safety profile in at least six patients, with fewer than one-third of patients experiencing a DLT during the first 21 days, was considered the recommended Phase II dose. In Part 2 (dose-expansion phase), the recommended Phase II dose was evaluated further for safety, PK, and preliminary activity in two tumour-specific expansion cohorts with an initially targeted enrollment of up to ~50 patients in total. In Cohort 1, eligible patients had platinum-sensitive high-grade serous or grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer with tumours harbouring a deleterious germline or somatic BRCA mutation (tBRCAmut, Arm A) or a tBRCA-like molecular signature (tBRCA-wild type [wt]/loss of heterozygosity [LOH]high, Arm B). Patients had received one to two prior platinum-containing regimens, with progression >6 months after the last dose of the most recent platinum therapy. In Cohort 2 (Arm C), patients had tBRCAmut or tBRCAwt/LOHhigh TNBC and had received at least one prior line of chemotherapy (without cancer immunotherapy) in the metastatic setting. Part 2 treatment comprised a 21-day run-in period of single-agent rucaparib at the identified recommended rucaparib starting dose (run-in), followed by rucaparib in combination with intravenous atezolizumab 1200 mg on Day 1 (combination). Cycles were repeated every 21 days.
All patients (Parts 1 and 2) were required to have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumour tissue available for planned analyses. In Part 2, biopsies were mandatory before starting rucaparib (if archival pre-treatment tissue was collected >90 days before treatment), after starting the rucaparib run-in phase before combination therapy, and at Days 15–21 of cycle 1 after initiating combination therapy. A further biopsy at disease progression was optional. Tumour and biomarker characteristics are described according to central review result. However, patients could be enrolled or assigned to a cohort based on local test results, to avoid delaying treatment initiation. In some cases, this resulted in a patient apparently being ineligible for the cohort in which they were treated. Additional inclusion criteria (beyond the disease-specific criteria for each cohort and arm mentioned above) included female aged ≥18 years, Eastern Cooperative Oncology Group performance status 0/1, life expectancy ≥3 months, measurable disease according to RECIST version 1.1, and adequate organ function. Patients were ineligible if they had previously received treatment with a PARPi, CD137 agonist, or other ICI (including but not limited to anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies).
After initiating study treatment, all AEs were to be reported until 30 days after the last dose of study treatment (90 days for serious AEs and AEs of special interest) or until the start of another anti-cancer therapy, whichever occurred earlier. Serious AEs and AEs of special interest that were considered related to study treatment were to be reported indefinitely. During the treatment period, tumours were assessed every 9 weeks during the first year and subsequently every 12 weeks until the end-of-treatment visit or radiographic disease progression based on RECIST version 1.1, as assessed by the investigator. For patients discontinuing study treatment for a reason other than disease progression or death, subsequent tumour assessments were to be performed every 12 weeks until radiographic disease progression based on RECIST version 1.1, initiation of further systemic cancer therapy, or death, whichever occurred first. Patients were asked to return 120 days after the last dose of atezolizumab for collection of blood samples for PK and ADA analyses. Non-compartmental analysis of PK data was performed when intensive collection was available.
PD-L1 and CD8 immunohistochemistry
Immunohistochemistry (IHC) assays were performed at CellCarta (Antwerp, Belgium) on 4-µm FFPE tissue sections. PD-L1 protein level was assessed with the PD-L1 IHC SP142 assay (Ventana Medical Systems, Tucson, AZ, USA) [34] and was characterised according to PD-L1 expression on TCs (percentage of total TCs expressing PD-L1) and tumour-infiltrating ICs (proportion of tumour area occupied by PD-L1 staining ICs of any intensity). PanCK–CD8 duplex IHC used the SP239 anti-CD8 clone (catalogue no. M5394; Spring Bioscience, Pleasanton, CA) and the AE1/AE3/PCK26 anti-Pan-Keratin clone (catalogue no. 760-2135; Roche Tissue Diagnostics, Rotkreuz, Switzerland) and was scored using the manufacturer’s scoring methods (CD8+PanCK multiplex IHC assay; CellCarta, Gosselies, Belgium). The intratumoural CD8 + T-cell density was determined as the percentage of CD8-stained cells occupying the defined tumour area.
A multiplex CD3/FOXP3 immunofluorescence assay was performed to assess percentages of T-regulatory cells (Tregs) among all T cells (percentage of CD3/FOXP3 double-positive staining cells of all CD3-positive cells in the defined tumour area [35]).
Genomic next-generation sequencing FoundationOne Panel
The FoundationOne (F1CDx) assay (FoundationOne, Cambridge, MA, USA) was performed retrospectively on FFPE tumour tissue section DNA samples from Part 1 patients. In Part 2, F1CDx assay results were used to pre-select patients with BRCA mutations and/or gLOH ≥16% (the refined cut-off established from ARIEL2 [36] and used in ARIEL3 [6]) for enrolment. The manufacturer’s algorithms were used for detailed content and mutation, gLOH, microsatellite instability (MSI), and tumour mutational burden (TMB) calling [37]. The gLOH algorithm has been validated only in tissue samples with >35% tumour content from ovarian cancer [6]. TMB and MSI were determined as previously described [38].
RNA analyses
Macrodissection was performed on sections of resected or core needle biopsy FFPE tumour tissue to enrich tumour percentage to >50% before RNA extraction. RNA was extracted from four to five sections of 4-µm FFPE tissue from pre-treatment and on-study tissue resections and biopsies from patients enrolled in Part 2. RNA sequencing was performed using TruSeq RNA Exome technology (Illumina, San Diego, CA, USA) at Q2 Solutions (Durham, NC, USA). RNA sequencing reads were first aligned to ribosomal RNA sequences to remove ribosomal reads. The remaining reads were aligned to the human reference genome (National Center for Biotechnology Information Build 38) using Genomic Short-read Nucleotide Alignment Program (GSNAP) version 2013-11-01. To quantify gene expression levels, the number of reads mapped to the exons of each RefSeq gene was calculated using the functionality provided by the R/Bioconductor package GenomicAlignments. For each cohort, raw counts for genes were trimmed mean of M-values (TMM)-normalised based on size factors as calculated with CalcNormFactors in the edgeR package. The TMM-normalised counts were subsequently voom transformed with the voom function in the limma package, resulting in normalised log2 counts per million (CPM) data. Gene features were filtered for low expression (defined as median CPM above the 25th percentile) and for low variance (defined as median CPM coefficient of variation above the 25th percentile). For RNA sequencing data, patient-matched paired t tests were performed to identify differentially expressed genes (DEGs) comparing run-in vs. pre-treatment, post-combination vs. run-in, and post-combination vs. pre-treatment, regardless of response status. Significant DEGs (P < 0.05 and >twofold change) were then analysed for their pathway enrichment through Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, CA, USA). Gene signatures are described in Supplementary Table 3.
The study was approved by the Institutional Review Board or Ethics Committee at each site before study initiation (NHS Health Research Authority reference 16/LO/2106). All patients provided written informed consent before undergoing any study-specific procedures. The study was conducted in full conformance with the International Conference on Harmonisation E6 guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of each country if they afforded greater protection to the individual.
Results
Patient population
Patients were enrolled from eight centres in the UK, France, Australia, and Spain between May 4, 2017, and February 18, 2019. The trial was discontinued prematurely because of slower than anticipated recruitment, after enrolment of nine patients in Part 1 (dose finding) and 19 patients in Part 2 (dose expansion) (10 patients with tBRCAmut ovarian cancer in Arm A, four patients with tBRCAwt/LOHhigh ovarian cancer in Arm B, and five patients with tBRCAmut or LOHhigh TNBC in Arm C).
Baseline characteristics are shown in Table 1. In Part 1, seven patients had ovarian-type cancer, and two had endometrial cancer.
Treatment exposure
The data cut-off for the final analysis reported here was August 5, 2020 (last patient last visit). By this date, all patients had discontinued from treatment and the study. Disease progression was mentioned as a reason for discontinuation of both atezolizumab and rucaparib in all but five patients. The last enrolled patient with TNBC was still deriving clinical benefit at the data cut-off and was transitioned to another trial enabling continued combination treatment with rucaparib plus atezolizumab. The median duration of follow-up was 15.2 months in Part 1 (range 5.0–36.1 months), 17.2 months in Part 2 Cohort 1 (ovarian cancer; range 2.9–27.8 months) and 10.7 months in Part 2 Cohort 2 (TNBC; range 5.8–19.1 months). Treatment exposure is shown in Supplementary Table 4.
Safety
Safety is summarised in Table 2. There were no DLTs in Part 1 (dose-finding phase evaluating rucaparib 400 or 600 mg twice daily) and the recommended dose for Phase II evaluation was rucaparib 600 mg twice daily in combination with atezolizumab 1200 mg on Day 1, repeated every 21 days. Across the entire study, there were no fatal AEs. Three patients discontinued study treatment because of AEs. The most common AEs across both parts of the study were gastrointestinal (nausea, diarrhoea, abdominal pain, constipation), fatigue, liver enzyme elevations, and anaemia (Table 3). The only grade 3/4 AEs of special interest for atezolizumab were grade 3 increased transaminase levels (in one patient receiving rucaparib 600 mg in Part 1 and three patients in Part 2 [one in each arm]) and maculopapular rash (in one patient receiving rucaparib 400 mg in Part 1 and the patient at 600 mg mentioned above with increased transaminase levels). Most cases of increased transaminase levels resolved (after rucaparib dose reduction in three patients). There were no cases of myelodysplastic syndrome or acute myeloid leukaemia. One patient experienced grade 4 bone marrow failure, which was considered symptomatic of disease progression but also related to rucaparib and concurrent illness.
Pharmacokinetics
Rucaparib PK analysis showed relatively rapid absorption and dose-proportional kinetics between 400 and 600 mg (Table 4). Rucaparib Tmax ranged from 1.5 to 6 h. There was moderate-to-high inter-individual variability in exposure ranging from 27.4–46.8% for Cmax, 28.6–88.7% for Cmin, and 21.2–41.6% for AUC across Parts 1 and 2. Steady-state profiles were relatively flat, and Cmax, AUC, and Cmin were highly correlated. Sparse PK sampling of atezolizumab showed similar atezolizumab exposure regardless of the rucaparib dose. There was low-to-moderate inter-patient variability, ranging from 7.0–35.3% for Cmax and 17.9–32.0% for Cmin, and all trough concentrations (Ctrough) exceeded the target concentration for maximal receptor occupancy of 6 μg/mL. Among 28 patients evaluable for ADA, one (4%) was positive for treatment-emergent ADAs.
Efficacy
In Part 1, one patient with tBRCAwt/LOHlow high-grade serous ovarian cancer/carcinosarcoma treated with rucaparib 600 mg achieved a partial response (PR) (17% response rate, 95% confidence interval [CI]: 0–64%) and five achieved stable disease (SD). In two patients with SD (both with high-grade serous ovarian cancer), the disease was stabilised for ≥6 months. Meaningful interpretation of biomarker findings is limited by the small patient numbers (Fig. 1a). However, of two patients with tBRCA1mut ovarian cancer, one showed clinical benefit (SD and PFS of 11.2 months). The only responder in Part 1 had a duration of response of 25.9 months and PFS of 27.2 months, and the highest PD-L1 IC expression (7%) among all nine enrolled patients. The patient achieving SD with PFS of 11.2 months had PD-L1 expression of 2% in ICs and the highest percentage of IC infiltrates (40%) and CD8 + T cells (10%) among all patients in Part 1. Of note, none of the nine patients enrolled in Part 1 had detectable PD-L1 expression in TCs (TC data not shown), TMB ≥ 10 mutations/megabase (Mut/Mb), or MSI high.
In Part 2, objective responses were achieved in six of 10 patients in Arm A (tBRCAmut ovarian cancer by local testing; 60% response rate, 95% CI: 26–89%, including one complete response [CR]) and one of four patients in Arm B (tBRCAwt/LOHhigh ovarian cancer by local testing; 25% response rate, 95% CI: 1–81%). Additionally, one patient with SD in Arm A and one in Arm B had PFS of ≥6 months. Among the five patients in Part 2 Arm C (tBRCAmut or LOHhigh TNBC according to local testing), two achieved a PR (40% response rate, 95% CI: 5–85%) and one patient with SD had PFS of 18.0 months.
Four of the five patients with ovarian cancer whose tumours were PD-L1 IC ≥ 1% and high CD8 (≥ median [4%]) achieved a PR or CR (Fig. 1b). One responder with ovarian cancer had TMB ≥ 10 Mut/Mb and tBRCAwt/LOHunknown (central assessment). None of the Part 2 patients had detectable PD-L1 expression on TCs or MSI high. The longest PFS among patients with ovarian cancer was 14.7 months (duration of response 12.9 months, OS censored at 17.8 months). According to local assessment, this patient had tBRCAmut disease.
Overall, 19 patients (68%) across all treatment arms had died by the analysis cut-off date. Death was from disease progression in 15 patients and unknown causes in four patients (Supplementary Table 5).
Longitudinal biomarker analyses
Figure 2a and Supplemental Table 2 summarise baseline and longitudinal biomarker sampling timepoints, datasets, and assays. Changes in the biological pathways associated with rucaparib MoA were apparent after combination therapy, including decreased cell cycle/proliferation and increased cell death and apoptosis RNA-based signatures (Fig. 2b). After the rucaparib run-in, DDR decreased in four of five responders but only one of four non-responders (by <10%; Fig. 2c). After combination therapy, DDR decreased further from run-in in all responders but in only one of two non-responders. The decrease in cell cycle signature expression post-combination vs. run-in was consistent with the trend in DDR and was seen only in responders. Conversely, three of the four non-responders had an increase after run-in or post-combination (Fig. 2c), indicating that tumours continued to grow and were resistant to therapy. In contrast, apoptosis signature expression increased in three of five responding patients during run-in, and increased further after combination therapy in two patients, whereas only one of four patients with SD or progressive disease (PD) had a modest (< 10%) increase in apoptosis.
Although global DEGs and IPA exploring the dynamics of immune modulation did not reveal any significantly enriched pathways related to tumour immune microenvironment (Fig. 2b), analysis of the dynamics of curated immune genes and signatures (Supplementary Table 3) revealed increased CD274 expression after rucaparib run-in in three of five responders but not in non-responders (Fig. 2d). However, after the addition of atezolizumab, both responders and non-responders had increased CD274 levels compared with run-in. During rucaparib run-in, there were dramatic increases in CD8 + T-cell activity (>50% increase) and cGAS-STING pathway activation (>100% increase) in four of five responders, and sustained or further increases after adding atezolizumab in two responders. In contrast, none of the four patients with SD/PD had >50% change in T-cell activity or cGAS-STING pathway at run-in and only one patient with SD had an increase (73%) in cGAS-STING pathway expression after combination therapy (Fig. 2d).
Increased expression of PD-L1 protein and CD8 + T-cell infiltration post run-in and combination therapy were validated with IHC analysis (Fig. 3).
We found no clear trend in Treg changes in association with RECIST response to treatment (Supplementary Fig. 1). In addition, among the eight patients with both baseline and longitudinal biopsies, changes in tumour-infiltrating CD8 + T cells generally (seven of eight patients) tracked with those of PD-L1 ICs (Supplemental Fig. 2), but Treg changes were more variable.
Discussion
In study Part 1 (dose-escalation phase), there were no DLTs and the recommended dose for Phase II evaluation was rucaparib 600 mg twice daily in combination with atezolizumab 1200 mg on Day 1, repeated every 21 days. This regimen demonstrated an acceptable safety profile consistent with the known effects of rucaparib and atezolizumab. There were no new safety signals and treatment discontinuation was infrequent. The PK profiles for both drugs were as expected. However, early study discontinuation due to poor enrollment in the dose-expansion phase limits conclusions on safety and efficacy.
Responses to rucaparib and atezolizumab combination therapy were observed predominantly in patients with BRCA-mutated tumours. These patients derived long-term benefit from therapy, consistent with published findings characterising long-term responders in two prospective studies of rucaparib in ovarian cancer [39]. The Phase II MEDIOLA study of durvalumab plus olaparib in PARPi-naive patients with germline BRCA1/2-mutant platinum-sensitive recurrent ovarian cancer showed a 72% ORR, median duration of response of 10.2 months, and median PFS of 11.1 months [40]. Although the 60% ORR with rucaparib and atezolizumab in BRCA-mutated ovarian cancer is numerically lower than the 72% ORR with durvalumab plus olaparib [40] and the 72% ORR with olaparib alone in patients with measurable disease in the SOLO3 trial [41], results from ongoing randomised trials are required to reliably assess the contribution of immune checkpoint blockade.
PD-L1 expression and CD8 + T-cell infiltration have previously been associated with better prognosis and/or response to ICIs in ovarian cancer and TNBC [42,43,44]. Although baseline biomarker data from our study do not allow robust conclusions, the only responding patient with ovarian cancer in Part 1 had the highest PD-L1 expression, and most responding patients with ovarian cancer in Part 2 also had PD-L1 IC ≥ 1%. Furthermore, in Part 2, four of the five patients with a high percentage of CD8 + T cells in the central tumour area achieved either PR or CR. This suggests that pre-existing immunity may enrich response to atezolizumab combination therapy. As expected in ovarian cancer [33], TMB was typically low, and only one patient across all treatment cohorts and arms had TMB ≥ 10 Mut/Mb (accompanied by high CD8 + T cells and high TILs).
The longitudinal biomarker analyses provide a unique opportunity to investigate the tumour intrinsic and microenvironment dynamics in patients receiving a PARPi and ICI in tandem. For tumour intrinsic features, we focused on known PARPi MoAs [1]. We observed decreased DDR and cell cycle and increased apoptosis pathway gene expression—expected MoAs of PARPis— in most responders but not in non-responders post run-in and post-combination. This observation suggests that the efficacy of rucaparib (and potentially combination) treatment is associated with decreased DNA repair and cell proliferation and, consequently, increased cell death. The DDR reduction at initial rucaparib treatment and accumulation of unrepaired DNA might also promote an anti-tumour immune microenvironment [29]. We observed preferential increases in PD-L1 gene and protein expression, CD8 + T-cell activity, and rucaparib-induced cGAS-STING pathway in responders after run-in and/or post-combination. Similar to previous reports that atezolizumab promoted PD-L1 expression in ICs in TNBC [45], we found increased PD-L1 expression at both mRNA and protein levels in ICs, independent of RECIST response status. Despite concerns that PARPi might promote proliferation and stabilise FOXP3 in Tregs, thereby suppressing immunity [46,47,48], in our study, CD3 + FOXP3+ Treg dynamic changes were not consistently increased upon rucaparib exposure. This suggests that the Treg changes might be related to a feedback of active immunity rather than a PARPi effect, although more in-depth mechanistic studies are required to answer this question definitively.
Exploration of the dynamics of immune modulation by rucaparib alone and with atezolizumab revealed no significantly enriched pathways related to tumour immune microenvironment, probably due to the small sample size and low expression of immune genes. However, consistent with previous findings in ovarian cancer cell lines showing induction of PD-L1 expression by PARPis [30], CD274 expression increased after rucaparib run-in in three of five responders but not in non-responders. Following the addition of atezolizumab, both responders and non-responders showed higher CD274 expression, consistent with enhanced PD-L1 expression with atezolizumab [45] independent of response. Increased CD8 + T-cell activity and cGAS-STING pathway activation were seen only in responders after the rucaparib run-in and were sustained or increased further with the addition of atezolizumab in both responders and non-responders.
Since this study was designed, results have been reported from the single-arm open-label Phase II TOPACIO/KEYNOTE-162 study evaluating a different PARPi (niraparib) combined with a different ICI (pembrolizumab) in TNBC or ovarian cancer. Among 55 patients with TNBC (enrolled irrespective of BRCA mutation or PD-L1 status), the RECIST ORR was 21% (90% CI: 12–33%), with a higher response rate among patients with BRCAmut than BRCAwt tumours (47% vs. 11%, respectively; median PFS 8.3 vs. 2.1 months, respectively) [49]. The ORR in 62 patients with platinum-resistant ovarian cancer was 18% (90% CI: 11–29%) and was similar irrespective of BRCA mutation status [50]. In the non-randomised Phase Ib/II JAVELIN PARP Medley study evaluating the PARPi talazoparib combined with the PD-L1 inhibitor avelumab, clinical activity was observed primarily in patients with BRCA-mutated tumours, with confirmed ORRs of 18% in TNBC and 64% in platinum-sensitive BRCA-mutated ovarian cancer [51]. In the Phase IIb tumour-agnostic JAVELIN BRCA/ATM study evaluating the same combination, durable responses were more common in BRCA-associated tumour types (including breast and ovarian cancers) than other tumour types, but the confirmed ORR of 26% was below the pre-specified 40% threshold [52]. Neither of these studies, which enrolled a notable proportion of patients with BRCA alterations across a range of tumour types, showed conclusive results on the predictive role of TMB for the PARPi/ICI combination.
An obvious limitation of our study is the small sample size, particularly in the BRCAwt/LOHhigh ovarian cancer and TNBC arms, because of premature discontinuation of the study given the changing landscape of ovarian cancer and TNBC, particularly regarding the use of PARP inhibitors in the treatment rather than maintenance setting. Additional limitations include the lack of serial biopsies from a small proportion of patients and reliance on local tumour assessment for molecular characterisation, which in some cases was discordant with central assessment. Only one patient with ovarian cancer in Part 1 and one in Part 2 had a centrally confirmed BRCAwt/LOHhigh tumour, precluding conclusions on whether this patient population can benefit from the combination therapy. The lack of reliable information on prior therapy and platinum-free interval in Part 1, which had less strict eligibility criteria, is a weakness and limits context-relevant understanding of the available efficacy information. Another limitation is that the trial was neither designed nor powered to study the effect of the combination on patients with homologous recombination-proficient tumours or to investigate the independent effect of atezolizumab. Furthermore, in the rapidly evolving treatment landscape, most patients with BRCA-mutated or HRD tumours will now receive a PARPi as maintenance therapy after front-line therapy, which affects treatment choices and outcomes in the recurrent setting. Thus, the relevance of this combination in recurrent disease is perhaps diminishing. Several Phase III trials are evaluating ICIs and PARPis in various combinations and settings, including ANITA (NCT03598270), ATHENA-COMBO (NCT03522246) [53], DUO-O (NCT03737643), ENGOT ov-44/FIRST (NCT03602859), and ENGOT-ov34/KEYLYNK-001 (NCT03740165), as well as a randomised Phase II trial (NCT02849496) exploring olaparib with or without atezolizumab in BRCA-mutated HER2-negative advanced breast cancer. In addition, in the MEDIOLA cohort without germline BRCA mutations, a triplet regimen of olaparib, durvalumab, and bevacizumab demonstrated high activity with median OS exceeding 2.5 years [54].
The trial was originally designed to determine the safety and tolerability of the combination and identify a potential recommended dose for further evaluation. Given the changing landscape, the translational research, which was integral to the study from the outset, is now perhaps the most informative aspect of the trial, providing first in vivo evidence of the MoA for this combination. This insight may guide more targeted development of such regimens. Trials randomising patients to PARP inhibition with or without immune checkpoint blockade (for example, the Phase III ATHENA-COMBO trial, which includes a translational research component [53]) will provide further insight into potential synergy. There remain many unanswered questions about the biological interactions of these two classes of agent but the present study represents an important first step. Preliminary signals suggest that activation of the cGAS-STING pathway during treatment may provide an early marker of benefit from therapy. If confirmed, STING pathway activation would provide reassurance that treatment continuation may be beneficial in responding patients, as well as helping to identify patients for whom an early switch to an alternative therapy may be beneficial to avoid unnecessary continuation of ineffective treatment. The identification of more reliable pre-treatment biomarkers to improve patient selection for PARPis and immunotherapy remains an important research goal. In the rapidly evolving treatment landscape for gynaecological cancers, five randomised Phase III trials of anti-PD-L1 agents in newly diagnosed or recurrent ovarian cancer have failed to demonstrate significantly improved outcomes in unselected populations, while offering hints of efficacy in patients with the highest PD-L1 expression [21,22,23,24,25]. Therefore it may be important to limit future trials of immunotherapy agents to populations with high PD-L1 expression, while continuing to explore and develop novel patient selection and therapeutic strategies to improve clinical outcomes.
Data availability
For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli (https://vivli.org/ourmember/roche/). For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see https://go.roche.com/data_sharing. Anonymised records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in the risk of patient re-identification. All clinical, raw RNA sequencing data are deposited to the European Genome-Phenome Archive under accession number EGAS00001006100.
References
Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
Rudolph J, Jung K, Luger K. Inhibitors of PARP: number crunching and structure gazing. Proc Natl Acad Sci USA. 2022;119:e2121979119.
Rose M, Burgess JT, O’Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New Engl J Med. 2016;375:2154–64.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.
Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New Engl J Med. 2018;379:2495–505.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New Engl J Med. 2019;381:2416–28.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New Engl J Med. 2019;381:2391–402.
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New Engl J Med. 2017;377:523–33.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New Engl J Med. 2018;379:753–63.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. New Engl J Med. 2021;384:2394–405.
Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl J Med. 2018;379:2108–21.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–93.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof M, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.
Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New Engl J Med. 2022;387:217–26.
Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. New Engl J Med. 2022;386:556–67.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. New Engl J Med. 2020;382:810–21.
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021;39:1842–55.
Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1275–89.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard I-L, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22:1034–46.
Kurtz J-E, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al. ATALANTE/ENGOT-ov29 Investigators. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial. J Clin Oncol. 2023;41:4768–78.
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39:3671–81.
Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288.
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280–304.
Yang C, Xia B-R, Zhang Z-C, Zhang Y-J, Lou G, Jin W-L. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869.
Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311–9.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–20.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148–59.
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–98.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, et al. Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the IMagyn050 randomized clinical trial. Clin Cancer Res. 2023;29:1698–707.
Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302–11.
Ung C, Kockx MM. Challenges and perspectives of immunotherapy biomarkers and the HistoOncoImmune™ methodology. Exp Rev Precis Med Drug Dev. 2016;1:9–24.
Coleman RL, Swisher EM, Oza AM, Scott CL, Giordano H, Lin KK, et al. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: a phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). J Clin Oncol. 2016;34:5540.
FoundationOne® CDx technical information. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006C.pdf (accessed November 25, 2021).
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.
Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, et al. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecol Oncol. 2021;163:490–7.
Drew Y, Kaufman B, Banerjee S, Lortholary A, Hong SH, Park YH, et al. Phase II study of olaparib + durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol 2019;30 (Suppl 5):v485 (Abstract 1190PD).
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164–74.
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113:1005–16.
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290.
O’Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12:394–400.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C. Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J Immunol. 2010;184:3470–7.
Luo X, Nie J, Wang S, Chen Z, Chen WJ, Li D, et al. Poly(ADP-ribosyl)ation of FOXP3 protein mediated by PARP-1 protein regulates the function of regulatory T cells. J Biol Chem. 2015;290:28675–82.
Gu W, Ge R, Zhu F, Li D, Liang R, Ge J, et al. PARP-1 inhibitor-AG14361 suppresses acute allograft rejection via stabilizing CD4+FoxP3+ regulatory T cells. Pathol Res Pr. 2020;216:153021.
Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132–40.
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5:1141–9.
Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, et al. Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP Medley nonrandomized controlled trial. JAMA Oncol. 2023;9:40–50.
Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, et al. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial. JAMA Oncol. 2023;9:29–39.
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, et al. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021;31:1589–94.
Banerjee S, Imbimbo M, Roxburgh P, Kim J-W, Plummer R, Stemmer S, et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. Ann Oncol. 2022;33(S7):S788.
Acknowledgements
The authors thank the patients who participated in this trial and their families, as well as the nurses, research coordinators, data managers, and clinical study site investigators, and the National Institute for Health Research Lancashire Cancer Research Fund. The authors would also like to acknowledge Yulei Wang from Roche/Genentech Translational Medicine for guidance and suggestions on biomarker strategy and analyses, Cecilia Sedano and Brynn Spranza for coordinating biomarker sample management, assay implementation, and data management, Kushagra Gupta (formerly of IQVIA) and Andrii Stakhniv (Intego Group, LLC) for statistical support, and Jennifer Kelly (Medi-Kelsey Limited) for medical writing support.
Funding
The study was sponsored by Genentech, Inc. The study was funded by Roche/Genentech and Clovis. Atezolizumab was provided by Roche/Genentech. Rucaparib was provided by Clovis. Medical writing support was provided by Jennifer Kelly, MA (Medi-Kelsey Limited, Ashbourne, UK), funded by F. Hoffmann-La Roche Ltd.
Author information
Authors and Affiliations
Contributions
ML-H and LMo are responsible for the overall content as guarantors and as such they accept full responsibility for the finished work and the conduct of the study, had access to the data, and controlled the decision to publish. Concept and design: RK and KKL. Acquisition, analysis, or interpretation of data: RK, AL, AO, AR, AG, SC, AS, ML-H, JW, CSS, JX, KKL, LMo, YG, IR-C and LMi. Drafting of the manuscript: ML-H, LMo and YG. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: YG.
Corresponding author
Ethics declarations
Competing interests
RK: clinical trial funding (to her institution) from Clovis Oncology; clinical trial grants from Merck Sharp & Dohme; consultancy for Pharmaceutica and Shattuck Pharma; honoraria from Clovis Oncology, AstraZeneca, GlaxoSmithKline, and Incyte; travel support from AstraZeneca, GlaxoSmithKline, and Sierra Oncology; and participation on data safety monitoring boards or advisory boards for Clovis Oncology, AstraZeneca, BeiGene, Eisai, GlaxoSmithKline, Incyte, iTeos Therapeutics, PharmaMar and Roche. AL: fees (to her institution) for advisory boards and educational presentations from AstraZeneca, Clovis, MSD, and GSK and a grant for translational research from AstraZeneca; she is the principal investigator on trials funded by AstraZeneca, MSD, and GSK. AO: consulting/advisory roles for Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, ImmunoGen, Genmab, Mersana, GSK, Deciphera, AGENUS, Corcept Therapeutics, Eisai, EMD Serono, Medison, Merck Sharp & Dohme, Novocure, prIME Oncology, Shattuck Labs, Sutro Biopharma, ITeos Therapeutics, and Amgen; research funding (to her institution) from AbbVie, Abililty Pharmaceuticals, Advaxis, Aeterna Zentaris, Aprea Therapeutics, Clovis Oncology, Eisai, Roche, Regeneron, Agenus, AstraZeneca, BeiGene, Belgian Gynaecological Oncology Group (BGOG), BMS, Corcept Therapeutics, ImmunoGen, Iovance Biotherapeutics, Lilly, MedImmune, Merck, Merck Sharp & Dohme, Mundipharma Research, Novartis FarmacÃutica, Seagen, Seattle Genetics, Sutro Biopharma, Tesaro, and Verastem; and travel/accommodation/expenses from AstraZeneca, Clovis Oncology, PharmaMar, and Roche. AR: institutional grants from Eisai, PharmaMar, and Roche; honoraria from AstraZeneca, MSD, Clovis, GSK, PharmaMar, and Eisai; advisory board roles at AstraZeneca, MSD, Clovis, GSK, PharmaMar, and Eisai; and travel support from AstraZeneca, GSK, and PharmaMar. AG: honoraria from AstraZeneca, MSD, GSK, Clovis, and Roche. SC, CSS, LMo: Genentech employees and Roche shareholders. AS, ML-H: Roche employees and shareholders. JW: employee of Roche Products, Ltd, and a Roche shareholder. JX, KKL: former employees of Clovis Oncology. YG: former employee of Genentech. IR-C: honoraria from Abbvie, Advaxis, Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Deciphera, Genmab, GlaxoSmithKline, MERSANA, MSD Oncology, OxOnc, Pfizer, PharmaMar, Roche, and Tesaro; consulting/advisory roles for Abbvie, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Deciphera, Genmab, GlaxoSmithKline, Mersana, MSD Oncology, Pfizer, PharmaMar, Roche, and Tesaro; research funding from BMS and MSD Oncology; and travel/accommodation/expenses from Advaxis, AstraZeneca, BMS, Clovis Oncology, GlaxoSmithKline, PharmaMar, Roche, and Tesaro. LMi declares no competing interests.
Ethics approval and consent to participate
The study was approved by the Institutional Review Board or Ethics Committee at each site before study initiation. All patients provided written informed consent before undergoing any study-specific procedures. The study was conducted in full conformance with the International Conference on Harmonisation E6 guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of each country if they afforded greater protection to the individual.
Consent for publication
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kristeleit, R., Leary, A., Oaknin, A. et al. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer 131, 820–831 (2024). https://doi.org/10.1038/s41416-024-02776-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-024-02776-7
- Springer Nature Limited